Related Experiment Videos
The role of alpha-agonists in glaucoma therapy
1Johns Hopkins University School of Medicine, Baltimore, MD 21209-2226, USA.
Current Opinion in Ophthalmology
|March 8, 1997
Summary
Topical alpha-agonists like apraclonidine lower eye pressure and improve safety in eye surgeries. However, their role in chronic glaucoma treatment remains uncertain due to potential side effects.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Topical alpha-agonists have been used to lower intraocular pressure since the 1960s.
- Early agents like clonidine presented challenges with systemic hypotension.
- Apraclonidine, a more polar alpha-agonist, offers an improved safety profile.
Purpose of the Study:
- To evaluate the safety and efficacy of topical alpha-agonists.
- To assess the utility of apraclonidine in ophthalmic procedures.
- To discuss the potential role of alpha-agonists in chronic glaucoma management.
Main Methods:
- Review of historical data on clonidine, brimonidine, and apraclonidine.
- Analysis of apraclonidine's physicochemical properties and clinical outcomes.
- Discussion of potential benefits versus risks for chronic glaucoma treatment.
Main Results:
- Apraclonidine demonstrates an excellent therapeutic index due to limited systemic absorption.
- Prophylactic use of apraclonidine has enhanced safety in anterior segment laser procedures, cataract surgery, and vitrectomy.
- The long-term efficacy and safety for chronic glaucoma treatment are not yet established.
Conclusions:
- Apraclonidine is a valuable agent for improving safety in various ophthalmic surgical procedures.
- The potential disadvantages of alpha-agonists for chronic glaucoma, including tachyphylaxis and systemic effects, require careful consideration.
- Further research is needed to clarify the role of alpha-agonists in the long-term management of glaucoma.